This study tests a drug called repotrectinib to see if it is safe and works for children and young adults with certain types of cancer. These cancers have special changes in their genes called ALK, ROS1, or NTRK1-3 alterations. Genes are like instructions in our body, and sometimes they change in ways that cause cancer. The study has two parts:
Phase 1 checks safety by trying different doses in kids under 12 with serious cancers that haven't responded to other treatments. About 12 kids will join. Phase 2 tests how well repotrectinib works in young people aged 12 to 25 with cancers that have specific gene changes. Participants will be put into groups based on their cancer type and gene changes, including whether they have had certain treatments before.
- Study participants will need to meet specific health criteria to join.
- Some health conditions or medications might exclude participation.
- Participants will have regular health checks during the study.
Understanding gene alterations is key to this study. If interested, participants should discuss with their doctor to ensure they meet the requirements and understand the potential risks and benefits.